News

Earlier, Perforomist (formoterol fumarate) Inhalation Solution 20mcg/2ml vial was under revaluation by Sepracor, now known as Sunovion Pharmaceuticals. According to Dey Pharma, the two intended reissued patents and

The increase in revenue is driven by higher prescription volume and price inflation on brand drugs, offset by the impact of the increase in generic utilization. Catalyst‘s net

The FDA reserves final approval of the product, however, until all exclusivity or patent challenges have been resolved, specifically the current patent litigation brought against Intelliject by King

The double-blind, randomized and controlled trial is expected to compare two dose levels of CF101 to placebo. The company anticipates to recruit around 300 patients at 17 centers.

Net income was $2.61bn, compared to $2.48bn for the same period in the prior year. For the six months ended 2011 revenues were $33.49bn, compared to $33.71bn for

Caprelsa is indicated as a treatment of symptomatic or progressive medullary thyroid cancer in patients suffering from unresectable (non-operable) locally advanced or metastatic disease. The FDA approval for

Markison will also be a member of the board of the newly created standalone company, following the completion of the acquisition of Nycomed A/S by Takeda Pharmaceuticals. Previously,

The contracts are part of an ongoing effort to develop diagnostic tools and drugs to protect health and save lives in a radiological or nuclear emergency such as

The company expects to recruit patients in 70 centers in 11 European nations. In the trial, the preterm infants younger than 32 weeks of gestational age are randomized